NeurologyLive Friday 5 — October 2, 2020

October 2, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 2, 2020.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Focal Dystonia Accurately Identified by AI-Based Deep Learning Platform

The platform, dubbed DystoniaNet, was able to identify 3 varieties of focal dystonia in a matter of 0.36 seconds with almost 100% accuracy.

2: NeurologyLive, CMSC to Offer 2 Educational Webcast Programs in Multiple Sclerosis

The “Differing Perspectives on Multiple Sclerosis Nursing Care” and “Cannabis and MS: Helping Patients Understand Risks and Benefits” live virtual webinar programs will address key knowledge gaps across the provider and patient communities.

3: Jonathan Graff-Radford, MD: Blood Tests as a Diagnostic Innovation in Alzheimer Disease

The neurologist at Mayo Clinic detailed promising diagnostic tools, including the revelation of blood tests in patients with Alzheimer disease.

4: Tuberous Sclerosis Complex Takes Major Step With Epidiolex Approval

Martina Bebin, MD, professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center, detailed the importance of cannabidiol for the treatment of TSC.

5: Eisai Initiates Phase 3 Trial of Lorcaserin in Dravet Syndrome

The primary objective of the trial is to demonstrate that lorcaserin has superior efficacy compared to placebo as measured by the percent change in frequency of convulsive seizures per 28 days.